Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease

Journal of Bone and Mineral Research

Volumn 27, Issue 1, 2012, Pages 38-46

  Stubbs, Jason R ^a   He, Nan ^a   Idiculla, Arun ^a   Gillihan, Ryan ^a   Liu, Shiguang ^b   David, Valentin ^c   Hong, Yan ^a   Quarles, L Darryl ^c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b GENZYME CORPORATION   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

CHRONIC KIDNEY DISEASE; FGF23; PHOSPHORUS; SECONDARY HYPERPARATHYROIDISM; VITAMIN D

Indexed keywords

CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; SODIUM PHOSPHATE COTRANSPORTER;

ALPORT SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; BONE TURNOVER; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY MASS; LONGITUDINAL STUDY; MALE; MINERAL METABOLISM; MORTALITY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PHOSPHATE EXCRETION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; AUTOANTIGENS; BODY WEIGHT; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; KIDNEY; LONGITUDINAL STUDIES; MICE; MINERALS; PHOSPHORUS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC;

EID: 84555187565     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.516     Document Type: Article

References (28)

1. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945-53. (Pubitemid 43924257)
2. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119: 2545-52.
3. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-92.
4. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE,. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009; 207: 546-51.
5. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16: 2205-15. (Pubitemid 41716454)
6. Miner JH, Sanes JR,. Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol. 1996; 135: 1403-13. (Pubitemid 27014609)
7. Cosgrove D, Meehan DT, Grunkemeyer JA, et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev. 1996; 10: 2981-92. (Pubitemid 26412525)
8. Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006; 291: E38-49. (Pubitemid 44035308)
9. Xiao Z, Awad HA, Liu S, et al. Selective Runx2-II deficiency leads to low-turnover osteopenia in adult mice. Dev Biol. 2005; 283: 345-56. (Pubitemid 40977954)
10. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
11. Miedlich SU, Zhu ED, Sabbagh Y, Demay MB,. The receptor-dependent actions of 1,25-dihydroxyvitamin D are required for normal growth plate maturation in NPt2a knockout mice. Endocrinology. 2010; 151: 4607-12.
12. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-8. (Pubitemid 44967731)
13. Craver L, Marco MP, Martinez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007; 22: 1171-6. (Pubitemid 46523434)
14. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH,. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995; 26: 622-31.
15. Wang M, Hercz G, Sherrard DJ, et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis. 1995; 26: 836-44.
16. Bostom AG, Kronenberg F, Ritz E,. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol. 2002; 13: 2140-4. (Pubitemid 34790792)
17. Levey AS,. Measurement of renal function in chronic renal disease. Kidney Int. 1990; 38: 167-84. (Pubitemid 20209447)
18. Ix JH, Shlipak MG, Wassel CL, Whooley MA,. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2010; 25: 993-7.
19. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19: 429-35. (Pubitemid 38787398)
20. Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008; 23: 1509-18.
21. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117: 4003-8. (Pubitemid 350224109)
22. Canalejo R, Canalejo A, Martinez-Moreno JM, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 21: 1125-35.
23. Isakova T, Gutierrez O, Shah A, et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol. 2008; 19: 615-23. (Pubitemid 351355405)
24. Gutierrez OM, Isakova T, Smith K, et al. Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrol Dial Transplant. 2010; 25: 3970-7.
25. Saji F, Shiizaki K, Shimada S, et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009; 111: 59-66.
26. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003; 112: 683-92. (Pubitemid 38057709)
27. Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab. 2008; 295: E254-61.
28. Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010; 78: 975-80.